Literature DB >> 25489108

Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Sara Crespillo1, Ana Cámara-Artigas2, Salvador Casares1, Bertrand Morel1, Eva S Cobos1, Pedro L Mateo1, Nicolas Mouz3, Christophe E Martin3, Marie G Roger3, Raphaelle El Habib4, Bin Su5, Christiane Moog5, Francisco Conejero-Lara6.   

Abstract

During HIV-1 fusion to the host cell membrane, the N-terminal heptad repeat (NHR) and the C-terminal heptad repeat (CHR) of the envelope subunit gp41 become transiently exposed and accessible to fusion inhibitors or Abs. In this process, the NHR region adopts a trimeric coiled-coil conformation that can be a target for therapeutic intervention. Here, we present an approach to rationally design single-chain protein constructs that mimic the NHR coiled-coil surface. The proteins were built by connecting with short loops two parallel NHR helices and an antiparallel one with the inverse sequence followed by engineering of stabilizing interactions. The constructs were expressed in Escherichia coli, purified with high yield, and folded as highly stable helical coiled coils. The crystal structure of one of the constructs confirmed the predicted fold and its ability to accurately mimic an exposed gp41 NHR surface. These single-chain proteins bound to synthetic CHR peptides with very high affinity, and furthermore, they showed broad inhibitory activity of HIV-1 fusion on various pseudoviruses and primary isolates.

Entities:  

Keywords:  HIV-1 neutralization; X-ray crystallography; coiled coil; drug design; fusion inhibitor

Mesh:

Substances:

Year:  2014        PMID: 25489108      PMCID: PMC4280599          DOI: 10.1073/pnas.1413592112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop.

Authors:  M Caffrey
Journal:  Biochim Biophys Acta       Date:  2001-05-31

3.  Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.

Authors:  Xi Chen; Lu Lu; Zhi Qi; Hong Lu; Ji Wang; Xiaoxia Yu; Yinghua Chen; Shibo Jiang
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

4.  Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

Authors:  Yiqun Deng; Qi Zheng; Thomas J Ketas; John P Moore; Min Lu
Journal:  Biochemistry       Date:  2007-03-20       Impact factor: 3.162

5.  Characterization of the steric defense of the HIV-1 gp41 N-trimer region.

Authors:  Debra M Eckert; Yu Shi; Sunghwan Kim; Brett D Welch; Eunchai Kang; Emily S Poff; Michael S Kay
Journal:  Protein Sci       Date:  2008-09-18       Impact factor: 6.725

6.  An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides.

Authors:  Pei Tong; Zhifeng Lu; Xi Chen; Qian Wang; Fei Yu; Peng Zou; Xiaoxia Yu; Yu Li; Lu Lu; Ying-Hua Chen; Shibo Jiang
Journal:  J Antimicrob Chemother       Date:  2013-06-21       Impact factor: 5.790

7.  Thermodynamics of peptide inhibitor binding to HIV-1 gp41.

Authors:  J L Cole; V M Garsky
Journal:  Biochemistry       Date:  2001-05-15       Impact factor: 3.162

8.  Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.

Authors:  Yuxian He; Shuwen Liu; Weiguo Jing; Hong Lu; Dongmei Cai; Darin Jeekin Chin; Asim K Debnath; Frank Kirchhoff; Shibo Jiang
Journal:  J Biol Chem       Date:  2007-07-06       Impact factor: 5.157

9.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

10.  International network for comparison of HIV neutralization assays: the NeutNet report.

Authors:  Eva Maria Fenyö; Alan Heath; Stefania Dispinseri; Harvey Holmes; Paolo Lusso; Susan Zolla-Pazner; Helen Donners; Leo Heyndrickx; Jose Alcami; Vera Bongertz; Christian Jassoy; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Quentin Sattentau; Hanneke Schuitemaker; Ruengpung Sutthent; Terri Wrin; Gabriella Scarlatti
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more
  14 in total

1.  Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.

Authors:  Yuanmei Zhu; Xiujuan Zhang; Xiaohui Ding; Huihui Chong; Sheng Cui; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Biol Chem       Date:  2018-02-07       Impact factor: 5.157

2.  Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.

Authors:  Xiyuan Wu; Zixuan Liu; Xiaohui Ding; Danwei Yu; Huamian Wei; Bo Qin; Yuanmei Zhu; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

3.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

4.  Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Authors:  Xiaohui Ding; Xiujuan Zhang; Huihui Chong; Yuanmei Zhu; Huamian Wei; Xiyuan Wu; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 5.  Designing helical peptide inhibitors of protein-protein interactions.

Authors:  Raheleh Rezaei Araghi; Amy E Keating
Journal:  Curr Opin Struct Biol       Date:  2016-04-25       Impact factor: 6.809

6.  De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics.

Authors:  Chao Wang; Wenqing Lai; Fei Yu; Tianhong Zhang; Lu Lu; Xifeng Jiang; Zhenqing Zhang; Xiaoyu Xu; Yu Bai; Shibo Jiang; Keliang Liu
Journal:  Chem Sci       Date:  2015-08-06       Impact factor: 9.825

7.  De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.

Authors:  Chao Wang; Lei Zhao; Shuai Xia; Tianhong Zhang; Ruiyuan Cao; Guodong Liang; Yue Li; Guangpeng Meng; Weicong Wang; Weiguo Shi; Wu Zhong; Shibo Jiang; Keliang Liu
Journal:  J Med Chem       Date:  2018-09-19       Impact factor: 7.446

8.  Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.

Authors:  Chao Wang; Xue Li; Fei Yu; Lu Lu; Xifeng Jiang; Xiaoyu Xu; Huixin Wang; Wenqing Lai; Tianhong Zhang; Zhenqing Zhang; Ling Ye; Shibo Jiang; Keliang Liu
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

9.  An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications.

Authors:  Wenqing Lai; Chao Wang; Fei Yu; Lu Lu; Qian Wang; Xifeng Jiang; Xiaoyu Xu; Tianhong Zhang; Shengming Wu; Xi Zheng; Zhenqing Zhang; Fangting Dong; Shibo Jiang; Keliang Liu
Journal:  Chem Sci       Date:  2015-12-03       Impact factor: 9.825

10.  Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.

Authors:  Danwei Yu; Yang Su; Xiaohui Ding; Yuanmei Zhu; Bo Qin; Huihui Chong; Sheng Cui; Yuxian He
Journal:  Viruses       Date:  2020-03-18       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.